In Brief: St. Jude
This article was originally published in The Gray Sheet
St. Jude: Initial implants of the firm's Angstrom MD and Contour MD implantable cardioverter defibrillator devices are performed in two patients Oct. 17 at the University of Kentucky Hospital, Lexington, following St. Jude's Oct. 2 receipt of an investigational device exemption to study the morphology detection technology incorporated in the single-lead ICD systems. The morphology detection algorithm enables the device to discriminate between atrial arrhythmias and ventricular arrhythmias "based on the characteristics of their electrogram complexes," St. Jude claims. The U.S. study will consist of 20 sites and will enroll 65 patients. European trials of the devices are ongoing ("The Gray Sheet" June 23, I&W-6)...
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.